product summary
Loading...
company name :
R&D Systems
product type :
protein
product name :
Recombinant Human IFN-beta 1a (Mammalian) Protein, CF
catalog :
11410-2
quantity :
1 MU
price :
948 USD
more info or order :
citations: 7
Reference |
---|
Witte K, Gruetz G, Volk H, Looman A, Asadullah K, Sterry W, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009;10:702-14 pubmed publisher
|
product information
master code :
11410-2
SKU :
11410-2
product name :
Recombinant Human IFN-beta 1a (Mammalian) Protein, CF
unit size :
1 MU
description :
The Recombinant Human IFN-beta 1a (Mammalian) Protein, CF from R&D Systems is derived from CHO.
target :
IFN-beta
category :
Proteins and Enzymes
conjugate :
Unconjugated
species :
Human
gene symbol :
IFNB1
accessionNumbers :
V00534
source short :
CHO
extended description :
A New rh IFN-beta is Available! It has lower endotoxin specifications, is made in-house, and is priced competitively!
USD :
948 USD
product details :
A New rh IFN-beta is Available! It has lower endotoxin specifications, is made in-house, and is priced competitively!
alt names :
Fibroblast interferon, IFB, IFBIFNB, IFF, IFNB, IFNB1, IFNbeta, IFN-beta, interferon beta, interferon, beta 1, fibroblast, MGC96956
storage :
Store the unopened product at 2 - 8 ░C. Do not use past expiration date.
more info or order :
company information

R&D Systems
614 McKinley Place N.E.
Minneapolis, MN 55413
Minneapolis, MN 55413
info@RnDSystems.com
https://www.rndsystems.com800 343-7475
headquarters: USA
R&D Systems develops and manufactures high-quality proteins and serves as a world leader in immunoassays. R&D Systems also produces quality antibodies, antibody arrays, stem cell and cell culture products, and cell selection and detection products, serving the life science and diagnostics industry.
related products
browse more products
questions and comments